Overview

Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential

Status:
Completed
Trial end date:
2020-04-16
Target enrollment:
Participant gender:
Summary
This study will be an open-label, randomized, three-period, six-sequence crossover study of GDC-9545 administered to healthy females of non-childbearing potential to determine the relative bioavailability of the Phase 3 capsule formulation to the Phase 1 tablet formulation in the fasted state and the effect of food on the Phase 3 capsule formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.